Grupp S, Maude S, Baruchel A, et al. Tisagenlecleucel appears effective and safe in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia with high-risk cytogenetic abnormalities. 24th Congress of EHA, abstract S1618.
PRO’s bij patiënten met FLT3-ITD-positieve AML die chemotherapie plus quizartinib ontvangen
mei 2026 | Leukemie